MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 152 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,546,545 | +9.4% | 12,659 | +4.3% | 0.01% | +25.0% |
| Q1 2024 | $3,241,599 | +15.8% | 12,139 | +0.4% | 0.00% | 0.0% |
| Q4 2023 | $2,798,541 | +61.0% | 12,095 | +1.6% | 0.00% | +33.3% |
| Q3 2023 | $1,738,022 | -52.1% | 11,901 | -24.2% | 0.00% | -40.0% |
| Q2 2023 | $3,627,162 | -1.9% | 15,702 | +2.9% | 0.01% | 0.0% |
| Q1 2023 | $3,695,676 | -18.0% | 15,255 | -1.7% | 0.01% | -28.6% |
| Q4 2022 | $4,506,422 | +352.5% | 15,526 | +1.3% | 0.01% | +250.0% |
| Q3 2022 | $996,000 | -11.3% | 15,329 | -2.3% | 0.00% | 0.0% |
| Q2 2022 | $1,123,000 | -17.2% | 15,691 | +13.6% | 0.00% | 0.0% |
| Q1 2022 | $1,356,000 | +7.6% | 13,815 | -7.1% | 0.00% | +100.0% |
| Q4 2021 | $1,260,000 | +10.8% | 14,874 | +4.4% | 0.00% | 0.0% |
| Q3 2021 | $1,137,000 | -25.5% | 14,250 | -9.0% | 0.00% | -50.0% |
| Q2 2021 | $1,526,000 | -1.1% | 15,663 | +18.7% | 0.00% | 0.0% |
| Q1 2021 | $1,543,000 | +5.0% | 13,192 | -0.2% | 0.00% | 0.0% |
| Q4 2020 | $1,469,000 | -6.4% | 13,217 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $1,569,000 | +5.0% | 13,217 | +0.2% | 0.00% | 0.0% |
| Q2 2020 | $1,494,000 | +63.1% | 13,190 | -3.8% | 0.00% | +50.0% |
| Q1 2020 | $916,000 | -15.7% | 13,715 | +14.9% | 0.00% | 0.0% |
| Q4 2019 | $1,087,000 | +3.5% | 11,936 | -2.0% | 0.00% | 0.0% |
| Q3 2019 | $1,050,000 | -16.7% | 12,177 | +1.2% | 0.00% | 0.0% |
| Q2 2019 | $1,261,000 | -5.9% | 12,031 | +12.4% | 0.00% | -33.3% |
| Q1 2019 | $1,340,000 | +9.4% | 10,700 | -1.5% | 0.00% | 0.0% |
| Q4 2018 | $1,225,000 | -46.1% | 10,866 | +2.4% | 0.00% | -25.0% |
| Q3 2018 | $2,273,000 | -8.6% | 10,614 | +19.4% | 0.00% | -20.0% |
| Q2 2018 | $2,487,000 | +195.7% | 8,893 | +23.5% | 0.01% | +150.0% |
| Q1 2018 | $841,000 | +38.8% | 7,199 | +9.1% | 0.00% | +100.0% |
| Q4 2017 | $606,000 | +104.0% | 6,600 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $297,000 | +153.8% | 6,600 | -8.3% | 0.00% | – |
| Q2 2017 | $117,000 | – | 7,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |